Bristol-Myers Squibb Co
BMY54.670USD
-0.040-0.07%
종가 12/26, 16:00（ET）시세는 15분 지연됩니다
111.31B시가총액
18.40P/E TTM
자세한 내용은 Bristol-Myers Squibb Co 회사
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
Bristol-Myers Squibb Co 정보
종목 코드 BMY
회사 이름Bristol-Myers Squibb Co
상장일Mar 17, 1980
CEOBoerner (Christopher S)
직원 수34100
유형Ordinary Share
회계 연도 종료Mar 17
주소Route 206 And Province Line Road
도시PRINCETON
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가United States of America
우편 번호08543
전화16092524621
웹사이트https://www.bms.com
종목 코드 BMY
상장일Mar 17, 1980
CEOBoerner (Christopher S)
Bristol-Myers Squibb Co의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Derica W. Rice
Mr. Derica W. Rice
Independent Director
Independent Director
--
--
Ms. Lynelle Hoch
Ms. Lynelle Hoch
President, Cell Therapy Organization, Member of the Leadership Team
President, Cell Therapy Organization, Member of the Leadership Team
--
--
Dr. Deepak L. Bhatt, M.D.
Dr. Deepak L. Bhatt, M.D.
Independent Director
Independent Director
--
--
Mr. Phil Holzer
Mr. Phil Holzer
Senior Vice President, Controller
Senior Vice President, Controller
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Christopher S. (Chris) Boerner, Ph.D.
Dr. Christopher S. (Chris) Boerner, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
63.90K
+1.88%
Ms. Karin Shanahan
Ms. Karin Shanahan
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
Executive Vice President, Global Product Development & Supply, Member of the Leadership Team
19.77K
+18.37%
Dr. Julia A. Haller, M.D.
Dr. Julia A. Haller, M.D.
Independent Director
Independent Director
13.62K
--
Mr. Adam Lenkowsky
Mr. Adam Lenkowsky
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
Executive Vice President, Chief Commercialization Officer, Member of the Leadership Team
12.44K
+87.05%
Ms. Cari Gallman
Ms. Cari Gallman
Executive Vice President, General Counsel and Chief Policy Officer
Executive Vice President, General Counsel and Chief Policy Officer
11.07K
+25.18%
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Dr. Manuel Hidalgo Medina, M.D., Ph.D.
Independent Director
Independent Director
--
--
수익 분석
통화: USD마지막 업데이트: Mon, Oct 6
통화: USD마지막 업데이트: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
기타
3.47B
28.29%
지역별USD
이름
수익
비율
United States
8.52B
69.44%
International
3.48B
28.37%
other
270.00M
2.20%
사업별
지역별
사업별USD
이름
수익
비율
Eliquis
3.68B
30.00%
Opdivo
2.59B
21.09%
Orencia
963.00M
7.85%
Revlimid
838.00M
6.83%
Yervoy
728.00M
5.93%
기타
3.47B
28.29%
주식 보유 통계
마지막 업데이트: Sun, Nov 16
마지막 업데이트: Sun, Nov 16
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
기타
74.21%
주주
주주
비율
The Vanguard Group, Inc.
9.58%
BlackRock Institutional Trust Company, N.A.
4.98%
State Street Investment Management (US)
4.74%
Charles Schwab Investment Management, Inc.
3.59%
JP Morgan Asset Management
2.90%
기타
74.21%
주주 유형
주주
비율
Investment Advisor
44.02%
Investment Advisor/Hedge Fund
25.70%
Research Firm
2.97%
Pension Fund
2.51%
Hedge Fund
2.51%
Bank and Trust
2.22%
Sovereign Wealth Fund
1.74%
Insurance Company
0.19%
Family Office
0.06%
기타
18.08%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
3973
1.68B
84.73%
-171.91K
2025Q3
4147
1.68B
85.10%
-5.79M
2025Q2
4212
1.69B
83.90%
+15.56M
2025Q1
4284
1.67B
82.20%
-238.41K
2024Q4
4280
1.64B
80.20%
+45.34M
2024Q3
4106
1.59B
79.76%
+6.69M
2024Q2
4097
1.58B
82.24%
-51.64M
2024Q1
4107
1.64B
80.22%
+12.13M
2023Q4
4104
1.60B
80.80%
-21.68M
2023Q3
4025
1.62B
80.17%
-24.04M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
193.94M
9.53%
+3.47M
+1.82%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
99.37M
4.88%
+1.60M
+1.64%
Jun 30, 2025
State Street Investment Management (US)
94.74M
4.65%
-94.48K
-0.10%
Jun 30, 2025
Charles Schwab Investment Management, Inc.
70.80M
3.48%
+10.20M
+16.82%
Jun 30, 2025
JP Morgan Asset Management
67.41M
3.31%
-2.47M
-3.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
46.18M
2.27%
+723.46K
+1.59%
Jun 30, 2025
Norges Bank Investment Management (NBIM)
33.57M
1.65%
-1.60M
-4.55%
Jun 30, 2025
Capital International Investors
66.16M
3.25%
-303.34K
-0.46%
Jun 30, 2025
Columbia Threadneedle Investments (US)
29.38M
1.44%
+350.53K
+1.21%
Jun 30, 2025
PRIMECAP Management Company
22.94M
1.13%
-25.98K
-0.11%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Fri, Dec 5
마지막 업데이트: Fri, Dec 5
이름
비율
VanEck Pharmaceutical ETF
9.15%
First Trust NASDAQ Pharmaceuticals ETF
7.58%
Franklin US Dividend Booster Index ETF
5.08%
WBI Power Factor High Dividend ETF
4.88%
VanEck Morningstar Wide Moat Value ETF
4.34%
iShares U.S. Pharmaceuticals ETF
4.31%
Schwab U.S. Dividend Equity ETF
3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
3.68%
ETC 6 Meridian Mega Cap Equity ETF
3.58%
Brookstone Value Stock ETF
3.48%
더 보기
VanEck Pharmaceutical ETF
비율9.15%
First Trust NASDAQ Pharmaceuticals ETF
비율7.58%
Franklin US Dividend Booster Index ETF
비율5.08%
WBI Power Factor High Dividend ETF
비율4.88%
VanEck Morningstar Wide Moat Value ETF
비율4.34%
iShares U.S. Pharmaceuticals ETF
비율4.31%
Schwab U.S. Dividend Equity ETF
비율3.74%
ETC 6 Meridian Hedged Equity Index Option ETF
비율3.68%
ETC 6 Meridian Mega Cap Equity ETF
비율3.58%
Brookstone Value Stock ETF
비율3.48%
주식 배당금
지난 5년 동안 총
22.71B
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Dec 10, 2025
BMY.NB Interim Cash Dividend of gross USD 0.63 paid on Feb 02, 2026 going ex on Jan 02, 2026 with reinvestment option
Jan 02, 2026
Feb 02, 2026
Jan 02, 2026
Sep 17, 2025
BMY.NB Final Cash Dividend of gross USD 0.62 paid on Nov 03, 2025 going ex on Oct 03, 2025 with reinvestment option
Oct 03, 2025
Nov 03, 2025
Oct 03, 2025
Jun 17, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Aug 01, 2025 going ex on Jul 03, 2025 with reinvestment option
Jul 03, 2025
Aug 01, 2025
Jul 03, 2025
Mar 03, 2025
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on May 01, 2025 going ex on Apr 04, 2025 with reinvestment option
Apr 04, 2025
May 01, 2025
Apr 04, 2025
Dec 11, 2024
BMY.NB Interim Cash Dividend of gross USD 0.62 paid on Feb 03, 2025 going ex on Jan 03, 2025 with reinvestment option
Jan 03, 2025
Feb 03, 2025
Jan 03, 2025
Sep 10, 2024
BMY.NB Final Cash Dividend of gross USD 0.6 paid on Nov 01, 2024 going ex on Oct 04, 2024 with reinvestment option
Oct 04, 2024
Nov 01, 2024
Oct 04, 2024
Jun 18, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Aug 01, 2024 going ex on Jul 05, 2024 with reinvestment option
Jul 05, 2024
Aug 01, 2024
Jul 05, 2024
Mar 01, 2024
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on May 01, 2024 going ex on Apr 04, 2024 with reinvestment option
Apr 05, 2024
May 01, 2024
Apr 04, 2024
Dec 06, 2023
BMY.NB Interim Cash Dividend of gross USD 0.6 paid on Feb 01, 2024 going ex on Jan 04, 2024 with reinvestment option
Jan 05, 2024
Feb 01, 2024
Jan 04, 2024
Sep 20, 2023
BMY.NB Final Cash Dividend of gross USD 0.57 paid on Nov 01, 2023 going ex on Oct 05, 2023
Oct 06, 2023
Nov 01, 2023
Oct 05, 2023
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
자주 묻는 질문
Bristol-Myers Squibb Co의 상위 5대 주주는 누구인가요?
Bristol-Myers Squibb Co의 상위 5대 주주는 다음과 같습니다:
The Vanguard Group, Inc.는 193.94M주의 주식을 보유하고 있으며, 전체 주식의 9.53%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 99.37M주의 주식을 보유하고 있으며, 전체 주식의 4.88%를 차지합니다.
State Street Investment Management (US)는 94.74M주의 주식을 보유하고 있으며, 전체 주식의 4.65%를 차지합니다.
Charles Schwab Investment Management, Inc.는 70.80M주의 주식을 보유하고 있으며, 전체 주식의 3.48%를 차지합니다.
JP Morgan Asset Management는 67.41M주의 주식을 보유하고 있으며, 전체 주식의 3.31%를 차지합니다.
The Vanguard Group, Inc.는 193.94M주의 주식을 보유하고 있으며, 전체 주식의 9.53%를 차지합니다.
BlackRock Institutional Trust Company, N.A.는 99.37M주의 주식을 보유하고 있으며, 전체 주식의 4.88%를 차지합니다.
State Street Investment Management (US)는 94.74M주의 주식을 보유하고 있으며, 전체 주식의 4.65%를 차지합니다.
Charles Schwab Investment Management, Inc.는 70.80M주의 주식을 보유하고 있으며, 전체 주식의 3.48%를 차지합니다.
JP Morgan Asset Management는 67.41M주의 주식을 보유하고 있으며, 전체 주식의 3.31%를 차지합니다.
Bristol-Myers Squibb Co의 상위 3대 주주 유형은 무엇인가요?
Bristol-Myers Squibb Co의 주요 주주 유형 상위 3가지는
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)입니다.
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)입니다.
Bristol-Myers Squibb Co(BMY)의 주식을 보유한 기관은 몇 개입니까?
2025Q4 기준으로, Bristol-Myers Squibb Co의 주식을 보유한 기관은 총 3973곳이며, 이들이 보유한 주식의 총 가치는 약 1.68B로 전체 발행 주식의 84.73%를 차지합니다. 이는 2025Q3 대비 -0.37% 증가한 수치입니다.
Bristol-Myers Squibb Co의 최대 수익원은 무엇인가요?
FY2025Q2 기준, Bristol-Myers Squibb Co의 Eliquis 부문이 가장 높은 매출을 기록했으며, 금액은 3.68B로 전체 매출의 30.00%를 차지했습니다.
